The MoDCs—derived in situ from tumor-infiltrating monocytes recruited by CSF-1 and CCL2—lack CCR7 expression and their anti-tumor activity would mostly entail an in situ activation of T-cell cytotoxicity in tumors. Here, CCR7 is linked to neoplasm.